Real-World Findings Suggest GLP-1 Drugs Offer Health Benefits for Young People with Diabetes
Researchers found use rose from 6.3% in 2019 to 27.2% in 2025, with improvements in weight, blood pressure and blood sugar control.
4 Articles
4 Articles
Study examines the real-world use of GLP-1 RA drugs in children and young people
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.
Real-world findings suggest GLP-1 drugs offer health benefits for young people with diabetes
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct. 2 examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.
"Our results confirm that GLP-1 receptor agonists have real benefits for children, adolescents and young adults with type 2 diabetes," researchers said.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
